Evaluation of the Safety and Efficacy of GSK Neisseria gonorrhoeae GMMA Investigational Vaccine in Healthy Adults Aged 18 to 50 Years

The primary objective of this study is to evaluate the **efficacy** of the GSK Neisseria gonorrhoeae GMMA (NgG) investigational vaccine in healthy adults aged 18 to 50 years. This First-Time-in-Human Proof-of-Concept (FTiH-PoC) study is crucial as it aims to provide an early assessment of the vaccine's ability to protect against infections caused by **Neisseria gonorrhoeae**, a pathogen for which there are currently no established immunogenicity correlates of protection. The study's findings could significantly impact the development of preventive strategies against this sexually transmitted infection, which remains a public health challenge due to increasing antibiotic resistance.

The clinical trial involves a total of **280 participants** who are being evaluated for the efficacy of an investigational vaccine against infections caused by **Neisseria gonorrhoeae**. The study population includes both male and female subjects, with an age range that falls within the category code "3," which typically represents adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The selection process and any additional inclusion or exclusion criteria have not been provided by the sponsor.

The clinical trial is designed to evaluate the **efficacy** and safety of an investigational vaccine targeting **Neisseria gonorrhoeae** in healthy adults aged 18 to 50 years. The study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the investigators are aware of the group assignments, thereby minimizing bias. The trial is expected to commence recruitment on August 25, 2023, and is projected to conclude by May 14, 2025, encompassing a total duration of approximately 21 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve obtaining informed consent, conducting a thorough medical history review, and performing necessary baseline assessments. Following successful screening, participants will be randomized into either the investigational vaccine group or the control group. Subsequent visits will be scheduled at regular intervals to monitor the participants' health, collect data on vaccine efficacy, and assess any adverse events. These follow-up visits are critical for evaluating the primary and secondary endpoints of the study.

The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted to gather comprehensive data on the vaccine's long-term effects. The expected length of participant involvement is approximately 21 months, aligning with the overall trial duration. Participants may be subject to early termination from the study if they experience significant adverse events, withdraw consent, or fail to comply with the study protocol. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data, contributing to the understanding of the investigational vaccine's potential in preventing infections caused by **Neisseria gonorrhoeae**.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatment protocols accurately.

The clinical trial is scheduled to commence recruitment on August 25, 2023, with an estimated completion date of May 14, 2025. The trial is categorized under phase 7, indicating an advanced stage of clinical research. Efficacy assessments will be conducted at predetermined intervals throughout the trial duration. The specific parameters or endpoints for evaluating efficacy, as well as the methods and tools for measurement, collection, and analysis, are not detailed in the provided data. The trial will adhere to a structured schedule to ensure consistent and reliable data collection, although the exact timepoints and instruments are not specified. The trial's design will focus on maintaining scientific rigor and objectivity in assessing the efficacy of the intervention under investigation.